Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
URGN
URGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
URGN News
UroGen Pharma Reports 2025 Financial Highlights
Mar 03 2026
NASDAQ.COM
UroGen Pharma Q4 2025 Earnings Call Highlights
Mar 02 2026
seekingalpha
UroGen (URGN) Q4 2025 Earnings Call Transcript
Mar 02 2026
NASDAQ.COM
UroGen Pharma Q4 Earnings Miss Expectations
Mar 02 2026
seekingalpha
UroGen's ZUSDURI Shows Efficacy at ASCO-GU 2026
Feb 27 2026
Newsfilter
Wildcat Capital Exits UroGen Pharma Position, Liquidating Approximately $6.79 Million
Dec 26 2025
Fool
Significant Options Trading on Wednesday: UTHR, URGN, DSGN
Dec 17 2025
NASDAQ.COM
D. Boral Capital Continues to Recommend Buying UroGen Pharma (URGN)
Oct 04 2025
NASDAQ.COM
Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks
Aug 19 2025
SeekingAlpha
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $40
Aug 11 2025
Benzinga
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Aug 07 2025
Benzinga
UroGen Pharma Q2 2025 Earnings Preview
Aug 06 2025
SeekingAlpha
UroGen Pharma Publishes Phase 3b Study Data Showing The Feasibility Of Home Instillation Of ZUSDURI
Jul 28 2025
NASDAQ.COM
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
Jul 28 2025
Newsfilter
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit
Jul 28 2025
Globenewswire
UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study
Jul 21 2025
NASDAQ.COM
Show More News
